685 US HIGHWAY ONE, NORTH BRUNSWICK, NJ
Investor Presentation
Amended material disclosure
Reports Second Quarter 2025 Financial Results for Legacy Operations and Provides Business Update
Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement
Provides Announcement on 2024 Annual Report to Comply with NYSE American Listing Rules
Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics, Investor Presentation
News, Material Contracts
Q2
Q1
FY 2024
Q3
FY 2023
Notice of Late Filing for Annual Report
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Amended Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Notice of Exempt Offering of Securities
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Definitive Merger Information Statement
PREM14C